CD44 and glioblastoma: In a recent study, miR-373-3p suppressed autophagyby targetingAKT1 in cervical cancer, which limited the growth of the tumor bothin vitro and in vivo.203 Furthermore, arecent study found that miR-338 might target ATF2 via the mTOR signalingpathway to suppress the proliferation and autophagy of cervical cancercells, indicating the possible use of miR-338 in the treatment ofthis disease.204 In a another study, miR-373was used to target the autophagy-upregulated proteins CD44 and TGFBR2in glioblastoma multiforme (GBM), which prevented the cancer cells’migration and invasion.205